Pharmacy and Wellness Review
Volume 1

Issue 1

Article 9

May 2010

The HIV VACCINE: Learning from Failure and Building on Success
Lindsey McClish
Ohio Northern University

Kimberly Gathers
Ohio Northern University

Katie Salay
Ohio Northern University

Lisa Vranekovic
Ohio Northern University

Kristin Seaman
Ohio Northern University

See next page for additional authors

Follow this and additional works at: https://digitalcommons.onu.edu/paw_review
Part of the Allergy and Immunology Commons, Community Health and Preventive Medicine
Commons, Immune System Diseases Commons, Other Pharmacy and Pharmaceutical Sciences
Commons, and the Preventive Medicine Commons
This Article is brought to you for free and open access by
the ONU Journals and Publications at
DigitalCommons@ONU. It has been accepted for
inclusion in Pharmacy and Wellness Review by an
authorized editor of DigitalCommons@ONU. For more
information, please contact digitalcommons@onu.edu.

The HIV VACCINE: Learning from Failure and Building on Success
Authors
Lindsey McClish, Kimberly Gathers, Katie Salay, Lisa Vranekovic, Kristin Seaman, and Kelly M. Shields

This article is available in Pharmacy and Wellness Review: https://digitalcommons.onu.edu/paw_review/vol1/iss1/9

Preventative Medicine

The HIV VACCINE: Learning from Failure and Building on Success
Li00sey M:Clish, lourth·year pharmacy major from Bellville, Ohio. Kimberly Gathera, fourth-year pharmacy maJOr from Mercer, Pa..
Kaue Salay, lour1h-year pharmacy majOr from Brecksville, OhK>, Lisa Vranekovic, filth-year pharmacy major from Concord Township. OhJO.
Kristin Seaman, filth-year pharmacy major from Mansfield, Ohio; Kelly M. Shields, PharmD

Abstract
An effecuve vaccme for acqUJred mmune deficiency syndrome (AIDS)
has eluded researchers since the identification of the HIV virus. There
are many challenges in developing an effective HIV vaccine, includ·
ing the lack ot knowledge regarding the immune response to the virus
and its diverse nature. Ethical concerns further complicate research.
A recent phase Ill trial was perlormed in Thailand and showed that a
sigrnficant reductK>n m HIV infection 1s possible. Pharmacists need to
stay informed of these important breakthroughs in AIDS research in order to provide quality health information to patients in their community
This paper auns to evaluate the pist failures and successes as welt as
explore the recent advancements towards finding a vaccine for HIV.
An esumated 33.4 m11ton 1nd1viduals worldwide are currently hving
with acquired immune deficiency syndrome (AIDS).' According to the
Centers for Disease Control and Prevention, approximately 56,300
new cases of Human lrnmunodetciency Virus (HIV) developed dunng
2006 in the United States alone. 2 A cure tor this disease has puzzled
and eluded rasearchers smce the 1dentihcalron of the HIV virus rn 1983.
However, hope IS on the honzon wrtb the advances m research that
could eventually lead to an effective HIV·1 vaccine. As one of the most
accessible heahh care providers, pharmacists need to stay informed on
these 1mµJrtant breakthroughs in HIVJAIDS research in order to provide
quality heahh infonnation to patients in their community.
Background
Although there is currently no cure for HIV, there are several effective anttretroviral tmarrnems available. Commencement of therapy is recommended
for all palienlS with a c04· count <350 cellstmm3 or in patienlS with an AIDSdefin1ng illness (PneumocysllS pneUTionia, Kaposi sarcoma, cryptococcostS,
etc.}. Goals of therapy currently include suppressing plasma HIV viral load,
redoc1ng HIV·assoctated morbidity and mortality, improving quality of fife,
restonng and i:xeserving immunologic function, and preventing HIV uansmission. The De~ent for Health and Human Services (DHHS) Panel
recommends several preferred and alternative complex multklrug regimens

rorHIV-positive patients. Treatment should be tndivldualtZed 00.sed on
virologic efficacy, toxicity, pill burden, dosing frequeocy, drug-<1rug interaction
potential, msistance testing msults and co-morbid condiOOns. 3 Despite great
improvements mdisease management for HIV/AIDS, the "first-fine therapy"
is avoidance ot infection in the first place. This has prompted interest in the
devalopment of an HIV vaccine.
The biggest challenge in developing an eff9ctive HIV vaccine is that
the immune response to the HIV infection is not fully understood. Research is further complicated because the virus is exrremely diverse and
consrantly changing. A successful vaccine would need to be effecuve
agamsr multiple forms of the virus. In many developing countries, the
most common strain of the virus 1s w1ld·type or non-mutated; whereas in
the U.S., med1cat1on-resistant HIV strains are of important concern. Wrth
a nse In the prevalence of HIV-2 and HIV· 112 viral strains 1n the United
States. development of successful vaccination formulat10ns becomes
even more difficult. Another obstacle mthe development of a vaccme
IS the fact that people with HIV cannot hght off the virus. and mounting
an immune response to a vaccine 1s necessary to prevent or reduce
infection. Other map r challenges include the inabihty to use attenuated
viruses in humans, absence of a small animal model, and relanvely little
pharmaceutical interest 4 Although it seems there are many impossible
rarriers to overcome, learning from the previous mistakes and successful outcomes of prior research have already Jed to significant advances
toward development of a successful vaccine.
Testing methods
HIV is an ever-elusive, ever-changing virus. It IS imp>rtam that the techniques and assays used mAIDS vaccine research improve as the virus
changes. Canarypox is the vector of chotee 1n developing a vaccine. It 1s
an anenuared virus that can carry a large quantty or foreign genes and
enter into human calls yet cannot grow or replicate wrthm them. lnrerferon·y
enzyme-finked 1mmunospot assays, or ELI Spot assays, are newer assay
technologies that allow detection of certain secreted cytokmes at a single
cell level. ualttanve enzyme-linked immunosol'OOnt assays. or ELI SAs,
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1987 FDA
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1997 President Clinton l'.J!)poses
goal of finding a vaccine in 10 years •
1998: First phase Ill clinical
Irials for HIV vaccine l:eg1n.•
1999: Firs1 human tnals rn a developing
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2003: AIDSVAX

tnal, first large
phase Ill human
lnal of an HIV
vaccine. Results
report no protec·
t!On against
HIV.•

2007: STEP (HVTN 502/MERCK 023) and PHAM·
BILI (HVTN503} piase llb lnals hahed because
data showed no ooneld and potential increase
in risk for HIV infection. The vaccine, MRK ·Ad5,
combined synthetic fragrrenls ol HIV wnh an adeno·
virus-oosed vector, expec1ed to produce a strong
immune response. Phase I and II tnals showed
promising rates of rmmunogenic responses.
2007: A phase II study ol an HIV·1canarypox
vaccine (vCP 1452) is JXJblished in lhe Journal of
.Acquired Immune Deficiency Syndromes.•
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are used to determine how many arnbodies are in a certain sample or how
much protein IS bound to the antibodies. Chromium release assays are also
frequently i:xirtormed. ThlS IS accomplished by incuooting infected cells 1n
chromium, and then, as the cells die by COS· CTL induced apoptostS, the
chromium IS released from the cell and can be measured as an rnd1cator of
effecbve immune response. These various methods of data analyses are
ulililed i11 ma11y curre11t AIDS vaccire studil:ls a11d am U1l:l 111eU10ds or ctl()i!..'e
in the followrng three tnal summaries.
Clinical trials
A phase Ill, community-based, randomized, multicenter, double-blind,
placebo-controlled trial was performed in Thailand to assess the efficacy
of four priming in)'lctions of a recombinant canarypox vector vaccine
and two booster in,actJons of a recombinant glycoprotein 120 subunit
vaccine. A total of 16,395 healthy men and women were recrrnted for
the study. Participants were monitored for HIV infection at the end of the
six-month vaccination senes and then every six months thereafter for
three years. Adverse reactions to the vaccines were mild ro moderate.
The vaccine group had a statistically significant lower infection rate compared to placebo {efficacy 31.2%, p < 0.04). The study had an extremely
large sample size and a long duration: however, it lacked correcoon for
possible lifestyle, disease state or ge net1c differences. This tnal showed
that a statistically sigrnficant reduction in HIV infection ls possible.
Further studies must be i:xirformed to examine the individual parameters
that could have led to such results. 11
A double-blind. randomized, phase II trial was performed to assess
the efficacy of HIV-1canarypox v~ccine candidate vCP1452 alone or
in combination with rgp1 20 subunit protein. Healthy HIV-1-uninfected
adults were recruited to participate. The vCP1452 alone was administered in the left arm to 120 participants, and protein rpg120 was administered in combination with vCP1452 to 120 participants in the right
arm. The remaming 90 participants received placebo. Overall, vCP 1452
and rpg 120 were well tolerated. A significant immune mob1hzat1on could
not be found in any of the four treatment groups with the vanous assay
methods. This study was Che first large, multicenter trial to test cell
secretion via the ELI Spot assay metllOd. It was performed to determine
if vCP1452 had a COS· CTL 1nduct1on frequency of at least 30 i:xircent.
since this 1nducti0n rate was not reached, plans for future vCP1452 trials
were abandoned.'

A phase I clinical trial was conducted on HIV-1-specific immune
responses rn healthy adult volunteers that received the mult:J-gene,
polyvalent, DNA prime-protein boost HIV- 1 vaccine tormulat1on DP6oo 1. HIV-1-negative adult volunteers or both genders were randomly assigned to either Group A or 8, and once these participants had received
the second protein boost and a safety review was conducted, enrollment
111 Gruuµ C was wrnµletl:ld. Tl1l:lrl:l were a tola of 27 volumeers. G1oups

A and B were administered 1.2 mg of DNA and at each vaccination
site, and group C was given a much higher dose of7.2 mg. Serum and
PBMC samples were collected periodically throughout the study to measure antibody and cell-mediated immune (CMI) rasponses. Participants
did not exhibit any serious adverse effects. Group C also demonstrated
a higher CMI response than Groups A and Band still showed fairly high
levels at the end of the trial (p<0.05). Analyses showed that the antibodies were widely cross-reactive against a range of HIV-1 Env ant:lgens
and were able to neutralize pseudotyped viruses that expressed the
primary Env antigens from several HIV-1 subtyf:X!S. Unfortunately, the
trial experienced reactogenicity in Group C causing investigators to rermrnate the study early in that group. Overall, !!le data demonstrated that
the ONA pnme-protein boost lmmumzat1on method rs an effective way to
generate humoral and CMI responses in humans. Moreover, the results
showed that a polyvalent Env formulation could produce extensive 1mmunogenrcity against a wide range of HIV-1 v1ruses. 10
Discussion
The Thailand trial was a critical breakthrough ooint in HIV/AIDS research
because vaccine efficacy against the HIV virus has been established
for the first time. Despite abandonment of the vCP1452 trial, it was still
of importance because it was the first to utilize new assay techniques.
According to researchers in the study using the OPS-001 vaccine, further
studies need to be conducted to assess the structural basis for antibody
and CMI cross reactivities. The arrangement of Env antigens should
be enhanced in order to increase the srrength of neutralrzing acuvities
against resistant viruses. Finally, before progressing ro more m-depth
human srud1es, the immunization schedule with adJUvant medicatt0n
regimen needs to be improved to reduce 1mmunogenic1ty of the DP6001 formulation. Future trials should focus on determining the body's
defense mechanisms against the HIV virus, this would allow tor more
specifrc vaccine targeting in order to improve immune system response.
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2008 A~set

study involving
cross-sullyJX!
ant11:xxJies ard
su00equent cellular
immune res~nses
indu:ed 1:1,t a ~ly
valent DNA HIV-1
vaccme (DP6-00I

formufat10n) is published in VaCCtne."

2009: ALV/JC-AIDSVAX (RV 144) ~se Ill tnal
completed, with mrtial data showing a 31 JX!rcent
risk redix:tt0n in oocoming infected with HIV when
1reated with a pnme-lxlost vaocme comblnatron
vs. placebo. No eltect was oooerved on viral load.
Data analyslS IS still ongoing.'
2009 The Thailand tnal, which studied the efficacy
of four pnm1ng miections of a recombinant canarypox vector vaccine and two lx>oster 1nject1ons of
a recombinant glycoprote1n 120 subunn vaccine,
IS pobhshed in Deceml:er in the New England
Journal of Medicine.•

2010: CDC 4370~ Phase II/Ill study forthe safety andelfrcacy of daily teoofovir-disopnxrl fumarate (TDF) as pre-ex~sure prophylaxis to prevent HIV infection an'Klng
inject10n drug wers.
CDC 4940 Phase Ill trial for the safety and effrcacy o1daily1erolovir-Orsoproxil
lumarate and emtncitabine (TOFiFTC) as pre-exµ:isure JX0phylax1S to prevent HIV
1nfec1ron arrong heterosexual sexually active young adults.'
2011: 1Pr£x Phase Ill trial of daily TOF/FTC as pre-exµ:isure pophylaxlS to preveni
HIV infection arrong homosexual sexually active men'
2012: HVTN 505 Randomized, placebo-controlled ptase 11 tnal evaluating safely
and efficacy of multiclade HIV· t DNAplasmid vaccine followed 1:1,t rnulticlade HIV-1
recomtxnam adeoovirat vector vaccine (prime-00os1strategy)1n redix:lllg viral load of
trose wt-o l:econ-e infected with HIV after receiving the vaccire c:onbnat10n.'
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While there IS an obvious role for an HIV vaccine, there are many
ethical concerns regarding the chrical efficacy testing. For some populauons, vaccine adm1msrrauon may actually put ind1v1duals at a greater
risk for developing the disease and/or may cause them to expenence
more rapid progress10n of the disease once infected, this was one of the
reasons for halting Merck's clinical trial 1n 2007. 11 Another mapr ethlC3.I
c::uncern 1:; tllal sludy µailicipanl\; may l1av~ fals~ exµictaLiuns upon
receiving the vaccine. For instance, if trial participants believe they have
developed immunity to the HIV virus resulting from vaccine administration, they may choose to participate in behaviors that could put them at a
greater risk for developing HIV (illegal drug use, sexual practices, etc. ).
Fortunately, evidence has ind cated that subjects in previous trials
have not engaged in behavioral disinhibition. 12 Most of these studies
also take place in undeveloped countries , where the need for an HIV
vaccine ts greatest However. because scientific and financial resources
for the development of these vaccines come from developed countnes,
there ts apprehension that the trials may not be conducted under stringent ethical and scientific standards. It is extremely important that all trial
participants are educated about the risks associated with receiving the
vaccine and informed that no vaccine has yet been clmJCally effective. If
any of these issues are not addressed before tnal m1tia!lon, the ethical
conduction of the tnal must be questioned. 11
Due to the fact that trials of a traditional model of vaccine have produced mixed results, some researchers have turned to more novel approaches in creating an HIV vaccine. For example, the Aaron Diamond
AIDS Research Center has begun research with ibalizumab, a monoclonal antibody that can block viral entry into the CD4• cell. Rather than
boosting the immune system and preparing the body to fight infection
like traditional vaccines, an ibalizumab vaccine would provide the body
with all the defenses necessary to fight the infection. 13

7. AIDS Vaccine Advocacy Coalition. HIV Preventt0n Research: Timeline
of Expected E/f1cacy Trial Results. 2010. www.avac.org!ht/d.contenlsJ
con1emtype_ld/18/order/date/direction/asc/pid/t891/cfrspaytype/iframe/after·
days/1200/beforedays/· 1215ffPL!T1meltne/Cfs/1. Accessed Jan. t3, 2010.
8. Relcs-Ngarm S, Pitisuttithum P, N1tayaphan S, Kaewkungwal J, ChiuJ, Paris
R. Vaccination with ALVAC ard Al DSVAA to pevenl HIV-11niect1on m
Thailard. N Eng J Med. 2009;361 . 2209 - 2220.
9. Russell N, GrahamB, Keefer M. McElrath M. Self S, We1ntold K, et al.
Phase 2 study of an HIV· 1canaryµix vaccine (vCP 1452) alone and 1n comtination with rpg120. J kquir Immune Defic Syrdr. 2007, 44(2):203 - 212.
10. Want S, Kennedy JS, West KMJntefiori DC, Coley S, Lawrerx:e J, et al.
Cross-sutxype antilxxfy and cellular immune resµimes irdu:ed cy a µily·
valent DNA prim-protein l:xlost HIV· 1vaccine in healthy human volunteers.
Vaxine. 20 February 2008;26(9). www.ocbi.nlrn.nih.gov/f:Xll:/ar1icles/
PMC2288749/?tool=pubred. Accessed Jan. 16, 2010.
11. Vel1kovic V, Veijkovic N, Glisic S. Ho MW. AIDS vaccine: Efficacy, safety,
and eth1CS. Vaccme. 200B;26 3072-3077.
12. Glornl HIV vaccine trials face ethical challenges. Medical Ethics Mvisor.
2007; 23: 142-3.
13. Park A. "David Ho: The Man Who Could Beat AIDS." Time. 25.Jan 2010.
www.11me.oornA1me/pnntout/0,68 16, 195'1703,00.html Accessed Jan. 28. 2010.

Conclusion
New and mnovaove ideas, comb1red with the knowledge from previous
research, are vital to the growth and development of a successful vaccine for HIV. Despite the many obstacles, advances have been made,
providing hope that someday HIV will no longer have the power to infect
a staggenng 56,300 American lives and millions more around the world
each year.
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